Products Categories
  • Ms.Sophie Chen
    Tel: +86-18133004126

  • Mobile:+8618133004126
  • Tel:+86-18133004126
  • Fax:0556-5800026
  • URL:http://www.hkpharm.cn
  • Province/state:Anhui
  • City:Anqing
  • Street:No.21, Huancheng West Road, Daguan District, Anqing City
  • MaxCard:
Home > Products >  ticagrelor

ticagrelor CAS NO.274693-27-5

  • Min.Order: 1 Gram
  • Payment Terms: L/C,D/P,T/T
  • Product Details

Keywords

  • ticagrelor; (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;
  • (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; Brilique; AZD 6140;
  • Ticagrelor API

Quick Details

  • ProName: ticagrelor
  • CasNo: 274693-27-5
  • Molecular Formula: C23H28F2N6O4S
  • Appearance: white power
  • Application: ANTIPLATELET
  • DeliveryTime: as customers demands
  • PackAge: DRUMS/CARTON
  • Port: HANGZHOU;SHANGHAI
  • ProductionCapacity: 10 Metric Ton/Month
  • Purity: 99
  • Storage: in sealed air resistant place
  • Transportation: air or sea or express delivery
  • LimitNum: 1 Gram
  • Valid Period: 24 month

Superiority

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Details

Ticagrelor is a new type of antiplatelet agglutinant, which was successfully developed by AstraZeneca in the United States. It is the world's first reversible combined oral P2Y12 adenosine diphosphate receptor antagonist. The drug is reversible. It acts on the purinoceptor2 (P2) subtype P2Y12 on vascular smooth muscle cells (VSMC), does not require metabolic activation, and has a significant inhibitory effect on platelet aggregation caused by adenosine diphosphate (ADP). It takes effect quickly after taking it and can effectively improve the symptoms of patients with acute coronary heart disease. Unlike thienopyridines, ticagrelor is a reversible inhibitor of P2Y12 receptors, so it is especially suitable for patients who need to undergo anticoagulation therapy before undergoing surgery. AstraZeneca began to develop ticagrelor in 1999. The European Society of Cardiology (ESC) announced the results of the Phase III trial of ticagrelor for the first time in 2009, detailing and comparing its effects on patients with acute coronary syndrome (ACS). Curative effect.

Ticagrelor's approval by the US Food and Drug Administration (FDA) is based on the results of PLATO clinical studies, which were also published in the famous "The Lancet" Lancet in 2010. PLATO is a randomized, double-blind, multi-center study involving 862 centers in 43 countries. A total of 18,624 patients hospitalized with acute coronary symptoms were included. All patients were randomly given aspirin plus ticagrelor or aspirin plus clopidogrel two antiplatelet treatment options. The results of the study showed that compared with patients taking clopidogrel, patients taking ticagrelor had a 16% lower risk of heart attack, stroke or death. The PLATO trial proved the benefits of ticagrelor for improving patient survival, and it is currently widely recommended as a treatment strategy for acute coronary syndromes. In addition, ticagrelor does not increase the overall risk of fatal bleeding events and other serious adverse reactions while reducing surgery-related myocardial infarction and thrombosis after stent implantation. Although ticagrelor has shown superiority over clopidogrel in the PLATO clinical study, ticagrelor has two disadvantages: one is that ticagrelor has to be taken twice a day instead of once a day like clopidogrel; the other is Ticagrelor can cause adverse reactions such as dyspnea, which is significantly more than clopidogrel. Ticagrelor has a half-life of only 12 hours, and it must be taken twice a day, which is a challenge for patients with poor compliance. After all, not all patients can fully comply with this method of administration. In practice, it has also been found that about 20% of patients treated with clopidogrel did not follow the doctor's instructions to take the medication, and these patients were even less likely to take ticagrelor in strict accordance with the prescribed dose. Therefore, for a rapidly reversible drug, stopping the drug directly is likely to increase the risk of acute thrombosis in the patient, leading to myocardial infarction or stroke.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog